Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hepion PharmaceuticalsHEPA +9.91% 3-Year ROIIC % is -729.92 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, Hepion Pharmaceuticals ranks worse than 91.98% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hepion Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -729.92%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hepion Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
HEPA's 3-Year ROIIC % is ranked worse than 91.98% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs HEPA: -729.92
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hepion Pharmaceuticals 3-Year ROIIC % Related Terms
Hepion Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Hepion Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HEPA vs AXIM, ZVSA, ISCO: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Hepion Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hepion Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hepion Pharmaceuticals's 3-Year ROIIC % falls into.
Hepion Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.761 (Dec. 2025) - -40.826448 (Dec. 2022) )
/
( 0.997 (Dec. 2025) - 6.075 (Dec. 2022) )
=
37.065448
/
-5.078
=
-729.92%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hepion Pharmaceuticals (HEPA) has a 3-Year ROIIC % of -729.92 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hepion Pharmaceuticals and its competitors. According to the industry distribution chart, Hepion Pharmaceuticals ranks #1216 out of 1322 companies in the Biotechnology industry, placing it in the top 92%.
Is Hepion Pharmaceuticals' 3-Year ROIIC % too high?
Hepion Pharmaceuticals' current 3-Year ROIIC % is -729.92. Based on the distribution chart, Hepion Pharmaceuticals ranks #1216 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Hepion Pharmaceuticals' 3-Year ROIIC % compare to AXIM and ZVSA?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #1216 out of 1322 companies for 3-Year ROIIC %. This places Hepion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current 3-Year ROIIC % is -729.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current 3-Year ROIIC % of -729.92. The current 3-Year ROIIC % is -729.92. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current 3-Year ROIIC % is -729.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HEPA has been successfully added to your 
